Why Clovis Oncology Shares Popped

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Clovis Oncology (NASDAQ: CLVS  ) , a clinical-stage biopharmaceutical company developing anti-cancer therapies, soared as much as 15% after reporting its fourth-quarter earnings results and providing its 2013 objectives.

So what: For the quarter, Clovis' net loss widened to $21.1 million from $14.4 million in the year-ago period. That's not surprising in one bit as it's spending more on clinical research. Clovis ended the quarter with $144.1 million in cash, and expects a cash burn of $53 million to $57 million for 2013. The real driver was CEO Patrick Mahaffy talking up the progress his company expects to make in 2013 with CO-1686 for non-small-cell lung cancer and with Rucaparib for ovarian cancer. Both drugs were moved into phase 1/2 monotherapy studies last year, and favorable results would start a chain of additional trials that Mahaffy outlined.

Now what: Clovis' ample cash position and the fact that it has two lead candidates advancing side-by-side has most investors stoked. As for me, I'm not nearly as enthusiastic. Let's not forget that Clovis was forced to shelve its experimental metastatic pancreatic cancer drug, CO-101, in November because it made no difference in overall survival when compared to Eli Lilly's Gemzar. Since then, the stock has recouped nearly all of its losses despite burning more cash and focusing on two drugs that are earlier in the development process than CO-101 was. The numbers just don't add up, and that's enough to make me keep a very safe distance from Clovis.

Craving more input? Start by adding Clovis Oncology to your free and personalized watchlist so you can keep up on the latest news with the company.

While you can certainly make huge gains in biotechs like Clovis, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 01, 2013, at 2:34 PM, Hope4GoodFuture wrote:

    "As for me, I'm not nearly as enthusiastic. Let's not forget that Clovis was forced to shelve its experimental metastatic pancreatic cancer drug, CO-101, in November..."

    Sean, I couldn't agree more. Management was incredibly self confident when talking about CO-101. This company was LEADING WITH CO-101 and everything else was a distant second, third, forth. Not only did this drug fail, but much of the work done by the company to create a clinical trial / investment thesis turned out to be bunk. The company has never explained how their research groundwork could have been so wrong (possibly non-existent?).

    My opinion? The only reason the stock price is so high is because the large investors who took this company public are smart. They know that individual investors in the biotech space are easily duped and have short memories. They know that if they hang on to their shares for a while they can exit when no one is expecting and make a tidy profit. Approval is so far away for these drugs currently in development and the odds of success SHOULD be significantly discounted (even more than low odds of any drug in early stage) based on CO-101 experience, but aren't.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2288359, ~/Articles/ArticleHandler.aspx, 9/25/2016 8:40:16 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,261.45 -131.01 -0.71%
S&P 500 2,164.69 -12.49 -0.57%
NASD 5,305.75 -33.78 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/23/2016 4:00 PM
CLVS $37.14 Down -1.22 -3.18%
Clovis Oncology CAPS Rating: ***